Adam Yaari

Adam Yaari holds the position of Co-Founder & CEO and has made notable contributions to the field of cancer research. His work primarily focuses on leveraging deep learning models and other advanced computational techniques to better understand cancer biology and treatment outcomes. Key publications co-authored by Yaari include ‘Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells’ (2020), which explores predictive models for cancer treatment responses. He also co-authored ‘Interpretation of cancer mutations using a multiscale map of protein systems’ (2021) and ‘Biologically informed deep neural network for prostate cancer discovery’ (2021), both of which enhance understanding of cancer mutations and their implications. Further, his research extends to genomic studies, as seen in ‘Genome-wide mapping of somatic mutation rates uncovers drivers of cancer’ (2022) and ‘Multi-resolution modeling of a discrete stochastic process identifies causes of cancer’ (2021). Additionally, Yaari has contributed to articles aimed at a broader scientific audience, including ‘New model helps identify mutations that drive cancer’ and ‘Digging into the dark matter of the genome to uncover mutations that drive cancer’ both published in 2022. His work not only advances the scientific community’s understanding of cancer but also aids in the development of more effective diagnostic and therapeutic strategies.